text stringlengths 1 5.46k |
|---|
PRESS RELEASE |
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets - Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology - Anima will receive an upfront payment of... |
NORTH CHICAGO, Ill. and BERNARDSVILLE, New Jersey, January 10, 2023 – AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biolog... |
About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and g... |
About Anima Biotech Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to... |
Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking sta... |
### |
SOURCE AbbVie Contact(s) AbbVie Media Frank Benenati (847) 938-8745 frank.benenati@abbvie.com Investors Liz Shea (847) 935-2211 liz.shea@abbvie.com Anima Biotech Media Kendy Guarinoni LifeSci Communications (724) 910-5868 kguarinoni@lifescicomms.com |
Schedule 11.2 Anima Disclosure Schedule |
1. Section 11.2.9: Anima will use Patent Rights within the UPenn Technology licensed to Anima by UPenn pursuant to the UPenn Agreement to conduct its obligations under this Agreement. Certain Patent Rights within the UPenn Technology are jointly owned by Anima and UPenn. For clarity, these Patent Rights within the UPen... |
Schedule 14.2.2 ADR Procedures |
Any Dispute referred to ADR under this Agreement shall be resolved as follows: |
1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the Dispute to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the arbitration, add additional issues to be resolved within the same AD... |
2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable independent, impartial, and conflicts-free neutral to preside in the resolution of all issues in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within s... |
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the Neutral shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the Parties. If the Parties cannot agree, the Neutral shall designate a ... |
4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the Neutral: |
(a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the Neutral; |
(b) a list of any witnesses such Party intends to call at the hearing and a short summary of the anticipated testimony of each witness; |
(c) a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed ruling shall not contain any recitation of the facts or any legal arguments, and the proposed remedy shall not include any punitive damages. The proposed ruling and the pr... |
(d) a brief in support of such Party's proposed rulings and remedies; provided that the brief shall not exceed twenty (20) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. |
Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. |
5. The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules: |
(a) Each Party shall be entitled to five (5) hours of hearing time to present its case. The Neutral shall determine whether each Party has had the five (5) hours to which it is entitled. |
(b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents, or other evidence, to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examinatio... |
(c) The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address therein not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR.... |
(d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments. |
(e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to all other matters, the Neutral shall have sole discretion regarding the admissibility of any evidence. |
6. Within seven (7) days following completion of the hearing, each Party may submit to the other Party and the Neutral a post-hearing brief in support of its proposed rulings and remedies; provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation sh... |
7. The Neutral shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one (1) of the Parties on each disputed issue but may adopt one (1) Party's proposed rulings and remedies on some issues and the other... |
8. The Neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: |
(a) If the Neutral rules in favor of one (1) Party on all disputed issues in the ADR, the losing Party shall pay one hundred percent (100%) of such fees and expenses. |
(b) If the Neutral rules in favor of one (1) Party on some issues and the other Party on other issues, the Neutral shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The Neutral shall allocate fees and expenses in a way that bears a reasonable r... |
9. The rulings of the Neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction. |
10. Except as provided in paragraph 9 or as required by law, the existence of the Dispute, any settlement negotiations, the ADR proceeding, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed to be Confidential Information of both Parties. The Neutral shall hav... |
11. All ADR proceedings shall be conducted in the English language, and the arbitration shall be seated in New York, New York, U.S.A. |
12. Each Party shall have the right to be represented by counsel in all aspects of any ADR proceeding. |
Confidential Execution Version |
AMENDED AND RESTATED LICENSE AGREEMENT |
between THE SCRIPPS RESEARCH INSTITUTE and ABBVIE GLOBAL ENTERPRISES LTD. |
Dated as of September 29, 2023 |
TABLE OF CONTENTS |
ARTICLE 1 DEFINITIONS ...................................................................................................... 1 |
ARTICLE 2 RESEARCH AND DEVELOPMENT PROGRAMS.............................................36 |
2.1 Target Program ..................................................................................................36 |
2.2 CD19 Program ...................................................................................................43 |
2.3 Platform Improvement Program .........................................................................44 |
2.4 Review of Plans .................................................................................................45 |
2.5 Research Program Manufacturing and Supply ....................................................45 |
2.6 Performance of Development Activities .............................................................46 |
2.7 AbbVie Materials ...............................................................................................47 |
2.8 Calibr Development Costs ..................................................................................47 |
2.9 Information and Reports .....................................................................................49 |
2.10 Data Packages ....................................................................................................50 |
2.11 Transition of Research Target Products. .............................................................52 |
ARTICLE 3 EXCLUSIVE LICENSE OPTIONS ......................................................................53 |
3.1 CD19 License Option .........................................................................................53 |
3.2 Platform Option .................................................................................................55 |
3.3 Calibr Cost-Sharing Option ................................................................................57 |
ARTICLE 4 GRANT OF RIGHTS; EXCLUSIVITY ................................................................59 |
4.1 Grants to AbbVie. ..............................................................................................59 |
4.2 Improvements to sCAR-T Platform ....................................................................60 |
4.3 Grants to Calibr; AbbVie Platform Improvements ..............................................60 |
4.4 Sublicenses ........................................................................................................61 |
4.5 Retention of Rights ............................................................................................61 |
4.6 Confirmatory Patent License ..............................................................................62 |
4.7 Exclusivity .........................................................................................................62 |
ARTICLE 5 DEVELOPMENT AND COMMERCIALIZATION BY ABBVIE........................67 |
5.1 In General ..........................................................................................................67 |
5.2 Diligence ...........................................................................................................67 |
5.3 Manufacturing Technology Transfer ..................................................................68 |
5.4 Subcontracting; Distributors ...............................................................................70 |
5.5 Development and Commercialization Reports ....................................................70 |
5.6 Regulatory Activities .........................................................................................70 |
ARTICLE 6 JOINT GOVERNANCE COMMITTEES .............................................................71 |
6.1 Target Discovery Joint Research Committee ......................................................71 |
6.2 CD19 Platform Proof-of-Principle Joint Development Committee .....................72 |
6.3 General Provisions Applicable to a Committee...................................................72 |
6.4 Decision-Making ...............................................................................................74 |
6.5 Working Groups. ...............................................................................................75 |
6.6 Alliance Managers .............................................................................................75 |
ARTICLE 7 PAYMENTS AND RECORDS .............................................................................75 |
7.1 Upfront Payments ..............................................................................................75 |
7.2 Platform Option Extension Fee ..........................................................................75 |
7.3 Platform Extension Payment ..............................................................................76 |
7.4 CD19 Autoimmune Option Fee ..........................................................................76 |
7.5 Non-Platform Option Milestones........................................................................76 |
7.6 Royalties ............................................................................................................78 |
7.7 Sublicensee Net Sales ........................................................................................82 |
7.8 Earnout Payments ..............................................................................................82 |
7.9 Estimated Sales Levels .......................................................................................83 |
7.10 Royalty Payments and Reports ...........................................................................83 |
7.11 Royalties on Calibr Sales ...................................................................................83 |
7.12 Mode of Payment ...............................................................................................84 |
7.13 Taxes .................................................................................................................85 |
7.14 Interest on Late Payments ..................................................................................86 |
7.15 Financial Records...............................................................................................86 |
7.16 Audit ..................................................................................................................86 |
7.17 Right to Offset ...................................................................................................87 |
7.18 Diagnostic or Veterinary Products ......................................................................87 |
7.19 Financial Obligations under In-License Agreements...........................................88 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.